Longevity of the novel ConvaTec infusion set with Lantern technology |
| |
| Authors: | Rayhan A. Lal MD Liana Hsu BS Jian Zhang MD Pernelle K. Schøndorff MS Matthias Heschel PhD Bruce Buckingham MD |
| |
| Affiliation: | 1. Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA;2. Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA;3. ConvaTec, Copenhagen, Denmark;4. Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA Stanford Diabetes Research Center, Stanford, California, USA |
| |
| Abstract: | Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set. |
| |
| Keywords: | CSII insulin pump therapy insulin therapy type 1 diabetes |
|
|
